Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lech-Marańda, Ewa
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined with Venetoclax for Treatment of Relapsed/Refractory AML	Recruiting	2	98	Europe	RVU120, SEL120, Venetoclax	Ryvu Therapeutics SA	Acute Myeloid Leukemia	02/26	09/26
RIVER-52, NCT06268574: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML	Recruiting	2	94	Europe, Canada	RVU120, SEL120	Ryvu Therapeutics SA	Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome	02/26	09/26
RIVER-51, NCT04021368: RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome	Active, not recruiting	1	112	Europe, US	RVU120(SEL120)	Ryvu Therapeutics SA	Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome	12/24	12/24